Omeros corporation provides update on interim analysis of artemis-igan phase 3 trial of narsoplimab in iga nephropathy

Seattle--(business wire)--omeros corporation (nasdaq: omer), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today provided an update regarding the interim analysis outcome in artemis-igan, the company's phase 3 trial evaluating narsoplimab for t.
OMER Ratings Summary
OMER Quant Ranking